IL122718A0 - Methods for treating diabetes - Google Patents

Methods for treating diabetes

Info

Publication number
IL122718A0
IL122718A0 IL12271896A IL12271896A IL122718A0 IL 122718 A0 IL122718 A0 IL 122718A0 IL 12271896 A IL12271896 A IL 12271896A IL 12271896 A IL12271896 A IL 12271896A IL 122718 A0 IL122718 A0 IL 122718A0
Authority
IL
Israel
Prior art keywords
methods
treating diabetes
diabetes
treating
Prior art date
Application number
IL12271896A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692725&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL122718(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL122718A0 publication Critical patent/IL122718A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL12271896A 1995-06-30 1996-06-26 Methods for treating diabetes IL122718A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71895P 1995-06-30 1995-06-30
PCT/US1996/010983 WO1997002004A2 (fr) 1995-06-30 1996-06-26 Procedes pour le traitement du diabete

Publications (1)

Publication Number Publication Date
IL122718A0 true IL122718A0 (en) 1998-08-16

Family

ID=21692725

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12271896A IL122718A0 (en) 1995-06-30 1996-06-26 Methods for treating diabetes

Country Status (14)

Country Link
US (1) US5756461A (fr)
EP (1) EP0836479A2 (fr)
JP (1) JPH11508895A (fr)
KR (1) KR19990028388A (fr)
CN (1) CN1195293A (fr)
AU (1) AU695934B2 (fr)
CA (1) CA2225454A1 (fr)
CZ (1) CZ416797A3 (fr)
EA (1) EA199800104A1 (fr)
HU (1) HUP9802609A2 (fr)
IL (1) IL122718A0 (fr)
NO (1) NO976063L (fr)
PL (1) PL324284A1 (fr)
WO (1) WO1997002004A2 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
EP0759441A3 (fr) * 1995-06-30 1999-06-30 Eli Lilly And Company Procédés de traitement des pathologies associées aux peptides neuropeptide Y
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6277592B1 (en) 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
WO1998012224A1 (fr) * 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Utilisation d'antagonistes de la leptine pour le traitement de la resistance insulinique dans les diabetes non insulino-dependants
AU739020B2 (en) * 1997-01-07 2001-10-04 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
AU2951797A (en) * 1997-06-06 1998-12-21 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
AU8671798A (en) * 1997-07-30 1999-02-22 Betagene, Inc. Methods and compositions relating to no-mediated cytotoxicity
AU763719B2 (en) 1997-12-08 2003-07-31 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US5866547A (en) 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999044598A2 (fr) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System APOPTOSE DE LA CELLULE-β DECLENCHEE PAR UN ACIDE GRAS
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
CA2328076C (fr) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Co-administration d'un inhibiteur de l'angiogenese pour renforcer la reponse immunitaire a mediation de proteine de fusion d'une cytokine d'anticorps
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
EP1118001A1 (fr) * 1998-10-02 2001-07-25 Amgen Inc. Procede permettant de determiner une predisposition a un traitement a la leptine
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2380331C (fr) * 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Complexes d'anticorps contenant plusieurs cytokines
CA2391080A1 (fr) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Formes d'erythropoietine dotees de proprietes ameliorees
CA2399832C (fr) 2000-02-11 2011-09-20 Stephen D. Gillies Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps
AU2001271729B2 (en) * 2000-06-29 2007-01-04 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
KR20090010127A (ko) * 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
WO2002079415A2 (fr) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US6899892B2 (en) * 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
RU2366664C2 (ru) * 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CN1961000B (zh) 2004-02-11 2011-05-04 安米林药品公司 具有可选择特性的杂合多肽
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
CA2617649A1 (fr) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2725143A1 (fr) * 2008-05-21 2009-11-26 Neurotez, Inc. Procedes de traitement de troubles cognitifs progressifs lies a la degenerescence neurofibrillaire
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
CN102552225A (zh) * 2010-01-25 2012-07-11 四川省中医药科学院 四氢姜黄素的新用途
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
US10046013B2 (en) * 2011-03-08 2018-08-14 The Trustees Of The University Of Pennsylvania Engineered bacteria for oral delivery of glucoregulatory proteins
JP6040464B2 (ja) 2011-07-08 2016-12-07 アエゲリオン・ファーマシューティカルズ・インコーポレイテッドＡｅｇｅｒｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP2900230B1 (fr) 2012-09-27 2018-08-15 The Children's Medical Center Corporation Composés pour le traitement de l'obésité et méthodes d'utilisation de ceux-ci
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
AU6479596A (en) 1997-02-05
JPH11508895A (ja) 1999-08-03
US5756461A (en) 1998-05-26
KR19990028388A (ko) 1999-04-15
WO1997002004A2 (fr) 1997-01-23
HUP9802609A2 (hu) 1999-03-29
EP0836479A2 (fr) 1998-04-22
WO1997002004A3 (fr) 1997-05-22
MX9800133A (es) 1998-03-29
CA2225454A1 (fr) 1997-01-23
EA199800104A1 (ru) 1998-10-29
NO976063D0 (no) 1997-12-23
NO976063L (no) 1998-02-16
PL324284A1 (en) 1998-05-11
CZ416797A3 (cs) 1998-06-17
CN1195293A (zh) 1998-10-07
AU695934B2 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
IL122718A0 (en) Methods for treating diabetes
GB9508248D0 (en) Process
GB9503382D0 (en) Process
GB9500675D0 (en) Process
GB9503385D0 (en) Process
GB9504922D0 (en) Process
IL125031A0 (en) Method for treating depression
GB9524752D0 (en) Modification process
IL124786A0 (en) Method for treating pain
GB9505377D0 (en) Process
AU7018794A (en) Methods for treating pathologies
GB9503383D0 (en) Process
GB9508490D0 (en) Process
EP0876352A4 (fr) Procede
AU4070897A (en) Method for treating diabetes
AP9701121A0 (en) Method for prearing streptogramines
GB9504708D0 (en) Process
GB9512427D0 (en) Process
GB2299809B (en) Process
GB9513130D0 (en) Treatment method
GB9513129D0 (en) Treatment method
GB9511594D0 (en) Treatment method
GB9505179D0 (en) Process for fluoroaromatics
GB9524764D0 (en) Modification process
GB9524763D0 (en) Modification process